Newsletter · · Ashutosh Agarwal

pTau-217 Blood Tests Go Direct to Consumer as Anti-Amyloid Stays Early Innings - The Neuro & Alzheimer's Pipeline - Week of June 28, 2026

Neuro and Alzheimer's pipeline newsletter for the week of June 22-28, 2026. A prescribing clinician says pTau-217 blood tests are now sold direct-to-consumer by quite a few labs, opening a validated-versus-unvalidated quality split underneath a real diagnostics TAM, while his candid anti-amyloid scorecard frames roughly 30% slowing as 'the beginning,' comparing the moment to where AZT stood for HIV.

The Neuro & Alzheimer's Pipeline

Week of June 28, 2026: pTau-217 Blood Tests Go Direct to Consumer as Anti-Amyloid Stays Early Innings

TL;DR

  • A prescribing Alzheimer's clinician says pTau-217 blood tests are now sold direct-to-consumer by "quite a few" labs, but warns the DTC versions aren't validated like the FDA-cleared one, and none are reliable yet in asymptomatic people. A quality/trust gap is opening underneath a real TAM.
  • Same clinician's candid anti-amyloid scorecard: it's the only way to clear plaque to PET-negative, but ~30% slowing is "the beginning," not the destination, "we are where AZT was for HIV." He prescribes to "many," not all.

What's new

Blood biomarkers are quietly going retail, and not all of them are good. On Brain Talk | Being Patient (June 23), Dr. Nathaniel Chin, a University of Wisconsin geriatrician who actually writes these scripts (OPERATOR), said "there are quite a few blood testing companies that are offering pTau-217 now" direct-to-consumer, comparing the arc to DTC genetic testing. The warning that matters for the names: "Not all tests are created equal," the FDA-cleared assay validated in MCI and dementia is not what "you might be able to get down the street," and none are reliable yet in pre-symptomatic people. Why it moves numbers: the bull case for Quanterix, C2N, Roche, Fujirebio, and Labcorp/Quest rests on pTau-217 becoming the front door to treatment. Commoditization widens the funnel but compresses price and puts a premium on the validated, reimbursed test, exactly the split Chin is describing.

The most honest anti-amyloid scorecard you'll hear from someone writing the prescriptions. Same episode, same speaker (OPERATOR): the two Phase 3 programs were "very well conducted," and clearing amyloid to a negative PET scan is something "no other intervention" can do, "a pretty remarkable accomplishment." But: "we just don't see the clinical benefit that we're hoping for." He frames ~30% slowing as meaningful-but-early, "we are where AZT was for HIV... we're just at the beginning," and expects real-world data past 18 months to show treated/untreated curves keep separating. In Wisconsin "we prescribe these medications, not for everyone, but for many." Why it matters: this is the demand-side reality beneath the Leqembi/Kisunla ramp, measured adoption, not a dam breaking.

A non-amyloid counter-narrative got a louder microphone than the drugs did. On Alzheimer's Breakthrough (June 25), trial investigators Dr. Josh Helman and Dr. Craig Tanio (OPERATOR, but caveat hard) walked through their "Evanthea" precision-medicine/lifestyle trial: ~90% of patients improved, north of a full standard deviation on CNS Vital Signs cognitive testing at nine months, versus decline in controls. They anchored explicitly against the drugs, "monoclonal antibodies cost $85,000," and floated Medicare paying via a global fee under coverage-with-evidence-development. Caveat: sub-$10M study, peer review pending, small and unblinded. Not investable. But it's the cheap "treat-the-whole-system" story that gains oxygen every quarter the drugs underwhelm, and a reminder that the CED/registry framework is the payer battleground.

Lilly's tape, not Lilly's pipeline. On Stock Market Today With IBD (June 26), the hosts (PUNDIT) flagged LLY up ~7% in a session, roughly two average true ranges, an "abnormally large move," on rotation into healthcare/pharma, and suggested IBB/XBI for those who don't want single-name biotech risk. No Kisunla, no donanemab, no payer color. Momentum, not fundamentals: tape, not thesis.

The debate

Does sub-Q dosing + blood biomarkers + broadening coverage turn anti-amyloid into a multi-billion franchise, or do modest efficacy, ARIA, and diagnostic bottlenecks keep uptake structurally weak while the tau bets stay unproven?

Bull (steel-manned from Chin): removing amyloid is real and unique; ~30% slowing compounds over time; the field is "building momentum"; biomarkers created the early-intervention window. A cheaper blood front-door plus more clinicians comfortable prescribing widens the funnel structurally.

Bear (also from Chin, and from the diagnostics warning): clinical benefit sits below what physicians "hoped for," patients still decline, and the burden makes many opt out. The diagnostic layer meant to feed the funnel is fragmenting into validated-vs-DTC, and the infrastructure to act on a positive test "isn't there yet." Meanwhile the loudest growth in patient-facing media this week was lifestyle reversal, not the drugs.

Stocks in play

  • LLY: Bull: healthcare rotation, ~7% session pop, relative strength. Bear: a chart story; no Kisunla launch data on the tape. Next catalyst: Q2 earnings / Kisunla script trends. (IBD, June 26)
  • QTRX, Roche, Fujirebio, Labcorp/Quest, C2N: Bull: pTau-217 going mainstream expands volume. Bear: DTC commoditization + validation gap pressures pricing and trust. Catalyst: guideline/payer adoption of the FDA-cleared assay. (Brain Talk, June 23)

Read-throughs

  • Blood diagnostics (QTRX, C2N, Roche, Fujirebio): mainstreaming is bullish for volume, but the "not all tests are equal" split favors the validated/reimbursed assay. (Brain Talk, June 23)
  • PET imaging (LNTH, GEHC): Chin still treats PET as the confirmatory standard a positive blood test routes to, supports the confirmatory-scan thesis. No direct LNTH/GEHC commentary this week. (Brain Talk, June 23)
  • Broader CNS / Parkinson's: an alternative-medicine show, Finding Genius Podcast (June 26), covered carbidopa-levodopa dyskinesia and LRRK2 subtypes. Fringe, flagged, not investable.